(Q38175862)

30 August 2017

title

Thinking out of the box--new approaches to controlling GVHD. (English)

1 reference

30 August 2017

Frédéric Baron

1

1 reference

30 August 2017

Stéphanie Humblet-Baron

2

1 reference

30 August 2017

Grégory Ehx

3

1 reference

30 August 2017

Sophie Servais

4

1 reference

30 August 2017

Muriel Hannon

5

1 reference

30 August 2017

Ludovic Belle

6

1 reference

30 August 2017

Chantal Lechanteur

7

1 reference

30 August 2017

Alexandra Briquet

8

1 reference

30 August 2017

Olivier Giet

9

1 reference

30 August 2017

Etienne Baudoux

10

1 reference

30 August 2017

Evelyne Willems

11

1 reference

30 August 2017

Yves Beguin

12

1 reference

30 August 2017

publication date

1 March 2014

1 reference

Current hematologic malignancy reports

30 August 2017

published in

1 reference

30 August 2017

volume

9

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

73-84

1 reference

Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Acute graft-versus-host disease: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell t

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Advances in graft-versus-host disease biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Mesenchymal stromal cells: a new tool against graft-versus-host disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Mesenchymal stromal cells: new directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Multipotent mesenchymal stromal cells and the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Immunomodulatory properties of mesenchymal stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Concise review: hitting the right spot with mesenchymal stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Mesenchymal Stromal Cells Fail to Prevent Acute Graft-versus-Host Disease and Graft Rejection after Dog Leukocyte Antigen-Haploidentical Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Immune tolerance: are regulatory T cell subsets needed to explain suppression of autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

T regulatory cell separation for clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

The best endpoint for acute GVHD treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

How I treat refractory acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Regulatory T cells in stem cell transplantation: strategies and first clinical experiences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3⁺ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Interleukin-2 and regulatory T cells in graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Mesenchymal stem cell as salvage treatment for refractory chronic GVHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0187-9

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

21 January 2018

1 reference

12 December 2020

Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse

1 reference

12 December 2020

Genzyme backs Osiris, despite Prochymal flop

1 reference

12 December 2020

Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease

1 reference

12 December 2020

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

1 reference

12 December 2020

The selective elimination of immunologically competent cells from bone marrow and lymphatic cell mixtures. II. Mouse spleen cell fractionation on a discontinuous albumin gradient

1 reference

12 December 2020

Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.

1 reference

12 December 2020

Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report

1 reference

12 December 2020

Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice

1 reference

12 December 2020

Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation

1 reference

12 December 2020

Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias

1 reference

12 December 2020

Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy

1 reference

12 December 2020

Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients

1 reference

12 December 2020

Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

1 reference

12 December 2020

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

1 reference

12 December 2020

Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire

1 reference

12 December 2020

The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study

1 reference

12 December 2020

Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation

1 reference

12 December 2020

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

1 reference

12 December 2020

Recognizing and managing chronic graft-versus-host disease

1 reference

12 December 2020

Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts

1 reference

12 December 2020

Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study

1 reference

12 December 2020

Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation

1 reference

12 December 2020

Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients

1 reference

12 December 2020

Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells?

1 reference

12 December 2020

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

12 December 2020

Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease

1 reference

12 December 2020

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

12 December 2020

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

1 reference

12 December 2020

Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation

1 reference

12 December 2020

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment

1 reference

12 December 2020

Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease

1 reference

12 December 2020

First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells

1 reference

12 December 2020

Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.

1 reference

12 December 2020

Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases

1 reference

12 December 2020

10.1007/S11899-013-0187-9

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1003581056

0 references

1 reference